|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor显示文摘In order to further promote the standardization of diagnosis and treatment of gastrointestinal stromal tumor(GIST) in China, the members of Chinese Society of Clinical Oncology(CSCO) Expert Committee on GIST thoroughly discussed the key contents of the consensus guidelines, and voted on the controversial issue. In final, the Chinese consensus guidelines for the diagnosis and management of GIST(2017 edition) was formed on the basis of 2013 edition consensus guidelines, which is hereby announced. The consensus included the pathological diagnosis,recurrence risk classification evaluation, targeted agent therapy, surgery and principles of surveillance of GIST. | jian li yingjiang ye jian wang bo zhang shukui qin yingqiang shi yulong he xiaobo liang xiufeng liu ye zhou xin wu xinhua zhang ming wang zhidong gao tianlong lin hui cao lin shen | 2017 | Chinese Journal of Cancer Research2017，29，4： | 104 |
| 2 | 中国胃肠间质瘤诊断治疗共识(2017年版)显示文摘近年来,胃肠间质瘤(gastrointestinal stromaltumor, GIST) 在诊断、治疗及研究领域取得快速进展,部分研究结果将对GIST临床诊疗实践产生重要影响。为了进一步推动我国GIST的规范化诊断和治疗,经中国临床肿瘤学会(Chinese Societyof Clinical Oncology, CSCO)胃肠间质瘤专家委员会对关键内容进行充分讨论,并对争议问题进行投票,最终,在2013年版共识基础上,形成了《中国胃肠间质瘤诊断治疗共识(2017年版)》,现予公布。 | 沈琳 曹晖 秦叔逵 叶颖江 李健 王坚 张波 汪明 高志冬 | 2018 | 肿瘤综合治疗电子杂志2018，4，1： | 216 |
| 3 | Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers显示文摘Objective: We aimed to evaluate the clinicopathologic characteristics, immunohistochemical expression and prognostic factors of patients with primary gastrointestinal stromal tumors(GISTs).Methods: Data from 2,570 consecutive GIST patients from four medical centers in China(January2001–December 2015) were reviewed. Survival curves were constructed by the Kaplan-Meier method, and Cox regression models were used to identify independent prognostic factors.Results: Of the included patients, 1,375(53.5%) were male, and the patient age range was 18 to 95(median, 58)years. The tumors were mostly found in the stomach(64.5%), small intestine(25.1%) and colorectal region(5.1%).At the time of diagnosis, the median tumor size was 4.0(range: 0.1–55.0) cm, and the median mitotic index per 50 high power fields(HPFs) was 3(range: 0–254). Of the 2,168 resected patients, 2,009(92.7%) received curative resection. According to the modified National Institutes of Health(NIH) classification, 21.9%, 28.9%, 14.1% and35.1% were very low-, low-, intermediate-and high-risk tumors, respectively. The rate of positivity was 96.4% for c-Kit, 87.1% for CD34, 96.9% for delay of germination 1(DOG-1), 8.0% for S-100, 31.0% for smooth muscle actin(SMA) and 5.1% for desmin. However, the prognostic value of each was limited. Multivariate analysis showed that age, tumor size, mitotic index, tumor site, occurrence of curative resection and postoperative imatinib were independent prognostic factors. Furthermore, we found that high-risk patients benefited significantly from postoperative imatinib(P<0.001), whereas intermediate-risk patients did not(P=0.954).Conclusions: Age, tumor size, mitotic index, tumor site, occurrence of curative resection and postoperative imatinib were independent prognostic factors in patients with GISTs. Moreover, determining whether intermediate-risk patients can benefit from adjuvant imatinib would be of considerable interest in future studies. | Xuechao Liu Haibo Qiu Peng Zhang Xingyu Feng Tao Chen Yong Li Kaixiong Tao Guoxin Li Xiaowei Sun Zhiwei Zhou | 2018 | Chinese Journal of Cancer Research2018，30，1： | 14 |
| 4 | 双镜联合技术在胃间质瘤中的应用效果显示文摘目的探讨双镜联合技术治疗胃间质瘤的安全性和有效性。方法回顾性分析2014年1月至2016年6月安徽医科大学第一附属医院治疗的胃间质瘤患者136例临床资料,其中采用双镜联合治疗患者44例、单纯胃镜治疗患者42例、单纯腹腔镜治疗患者50例。比较3种治疗方式的手术时间、术中出血量、术后胃肠道功能恢复时间、术后下床活动时间、术后住院时间,以及术后并发症发生率和肿瘤复发情况。结果所有患者均手术顺利,无术后死亡病例,所有患者术后随访均未见复发。双镜联合组操作时间、术中出血量、术后胃肠道功能恢复时间、术后下床活动时间、术后住院时间均短于或少于单纯腹腔镜组(P<0.05),单纯胃镜组肿瘤直径、操作时间、术后胃肠道功能恢复时间、术后下床活动时间、术后住院时间均短于或少于单纯腹腔镜组(P<0.05)。结论对于直径较小的胃间质瘤,单纯胃镜切除是最佳方案。双镜联合技术更适合治疗直径在10 cm以内较大的胃间质瘤,其操作安全可行,且具有定位准确,创伤小、术后恢复快的特点,近期疗效令人满意,但其远期疗效仍需进一步随访。 | 张震 李永翔 周玉良 | 2018 | 安徽医学2018，39，7： | 9 |
| 5 | 原发胃肠间质瘤临床病理特征及预后分析:附314例报告显示文摘目的:分析原发胃肠间质瘤(GIST)的临床病理特征及预后情况。方法:回顾分析中南大学湘雅医院2012年1月—2018年8月期间诊治的314例原发GIST患者的临床病理及随访资料。结果:314例GIST患者中,男性169例(53.8%),女性145例(46.2%),其中位年龄为55(24~86)岁,肿瘤直径为6(1~34)cm;原发部位位于胃165例(52.6%)、十二指肠15例(4.8%)、空回肠115例(36.6%)、结直肠6例(1.9%)、其他部位13例(4.1%)。根据改良NIH分级,其中极低危11例(3.5%)、低危109例(34.7%)、中危80例(25.5%)、高危114例(36.3%)。314例均接受手术治疗,其中R_0切除305例(97.1%)、R_1切除4例(1.3%)、R_2切除5例(1.6%)。268例(85.4%)获得有效随访,中位随访时间为37(2~69)个月。194例中高危患者中67例(34.5%)术后接受伊马替尼辅助治疗,中位治疗时间为26(7~56)个月。全组1、3、5年总体无复发生存率为97.0%、92.6%、81.7%,1、3、5年总体总存活率为99.4%、95.2%、88.2%。极低危、低危、中危及高危患者其5年无复发存活率分别为100.0%、93.3%、79.1%、64.4%,5年总存活率分别为100.0%、94.1%、91.7%、74.9%。194例中高危GIST患者中,67例术后接受伊马替尼辅助治疗者及127例术后未接受伊马替尼辅助治疗者5年无复发存活率分别为73.8%、65.2%,5年总存活率分别为87.5%、71.6%。结论:原发GIST最常见发病部位是胃和小肠,完整切除并根据危险度分级予以伊马替尼辅助治疗预后较好,但还需针对不同的高危GIST患者量身定制个体化治疗方案,并且在规范辅助治疗的同时,还需严密系统地随访。 | 赵丁民 廖国庆 刘盛 漆靖 朱从波 刘苇行 蔡高强 | 2019 | 中国普通外科杂志2019，28，4： | 8 |
| 6 | 1例肛周胃肠间质瘤病例报告并文献回顾显示文摘胃肠间质瘤(gastrointestinal stromal tumor,GIST)是胃肠道最常见的间叶源性肿瘤,临床表现常见腹痛腹胀、消化道出血、腹部包块,或者无临床症状,部分患者于体检时发现。临床上往往需要结合病理检查方可明确诊断。经文献检索发现,目前肛周胃肠间质瘤临床病例报告较少,加之该病临床表现缺乏特异性,极易误诊,故本文报告1例临床表现为右侧臀部包块,但经术后病理检查后确诊肛周胃肠间质瘤的病例诊治过程,与同道交流。 | 王宇 张宗文 余清华 张艺嘉 彭卫红 顾尽晖 | 2021 | 结直肠肛门外科2021，27，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员